Efficacy of drug regimen with and without oseltamivir in hospitalized patients with COVID-19: A retrospective study

Shokri, Fazlollah; Rezapoor, Saeed; Najafi, Masoud; Asadi, Mohsen; alavije, Mohammad Karimi; Abolhassani, Moussa; Moieneddin, Mohammad Hossein; Ashrafi, Amir Muhammad; Gholipour, Narges; Naderi, Parisa; Charati, Jamshid Yazdani; Alizadeh-Navaei, Reza; Saeedi, Majid; Heidary, Mohsen; Rostamnezhad, Mostafa

doi:10.1016/j.vacune.2023.04.005

ISSN: 2445-1460

Official journal of the Asociación Española de Vacunología (AEV)

Vacunas is a peer-reviewed journal supported by an advisory board of experts in the field of vaccinology. The aim of the journal is to contribute to the dissemination of the scientific advances made in the area of basic and applied research in the field of vaccine-preventable diseases in humans. It places special emphasis on aspects associated with planning and evaluation (epidemiology of vaccine-preventable diseases, development of vaccination programs, evaluation of the efficacy, effectiveness and efficiency of vaccinations). Vacunas publishes, in Spanish and in English, Editorials, Original Articles, Special Articles, Reviews, Strategies and Vaccination Programs. There are also sections on Literature Reviews, News and on Congresses associated with vaccinations. The peer review process is done anonymously by reviewers with expertise in the area of knowledge of each manuscript as well as experts in methodology or statistics, as determined by the Editorial board, which works towards maintaining an efficient editorial process in order for the manuscripts to be published as soon as possible.

See more Open Access Option

Indexed in:

Scopus, EMBASE/Excerpta Médica e IBECS

Subscribe:

Citescore

CiteScore measures average citations received per document published.

Citescore 2023

3.9

SJR

SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.

SJR 2023

0.423

SNIP

SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.

SNIP 2023

0.421

View more metrics

Journal Information

Previous article | Next article

Vol. 24. Issue 2.

Pages 141-149 (April - June 2023)

Export reference

Download PDF

More article options

Statistics

Visits

Vol. 24. Issue 2.

Pages 141-149 (April - June 2023)

Original

DOI: 10.1016/j.vacune.2023.04.005

Efficacy of drug regimen with and without oseltamivir in hospitalized patients with COVID-19: A retrospective study

Visits

Download PDF

Fazlollah Shokria, Saeed Rezapoorb, Masoud Najafic,d, Mohsen Asadie, Mohammad Karimi alavijef, Moussa Abolhassanig, Mohammad Hossein Moieneddinh, Amir Muhammad Ashrafii, Narges Gholipourj, Parisa Naderik, Jamshid Yazdani Charatil, Reza Alizadeh-Navaeim, Majid Saeedin, Mohsen Heidaryo,

Corresponding author

mohsenheidary40@gmail.com

Corresponding authors.

, Mostafa Rostamnezhadp,

Corresponding author

Rostamnezhad213@gmail.com

Corresponding authors.

a Department of Medical Genetics, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

b Department of Radiology, Imam Khomeini Hospital, Amol, Iran

c Medical Technology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran

d Radiology and Nuclear Medicine Department, Kermanshah University of Medical Sciences, Kermanshah, Iran

e Department of Hematology and Blood Banking, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

f Department of Infectious Disease, Imam Reza Hospital, Amol, Iran

g Inv. Member, International Federation of Inventors' Associations-IFIA, Geneva, Switzerland

h Student Research Committee, Amol Faculty of Nursing, Mazandaran University of Medical Sciences, Sari, Iran

i Student Research Committee, Amol Faculty of Nursing, Mazandaran University of Medical Sciences, Sari, Iran

j Department of Critical Care Nursing, School of Nursing and Midwifery (Nasibeh), Mazandaran University of Medical Sciences, Sari, Iran

k Department of Biology, Faculty of Cellular and Molecular Sciences, Central Tehran Branch, Islamic Azad University, Tehran, Iran

l Department of Biostatistics, Faculty of Health, Mazandaran University of Medical Sciences, Sari, Iran

m Gastrointestinal Cancer Research Center, Non-communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran

n Department of Pharmaceutics, Faculty of Pharmacy, Mazandaran University of Medical Science, Sari, Iran

o Cellular and Molecular Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran

p Department of Medical Physics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

This item has received

29 Visits

Article information

Abstract

Full Text

Bibliography

Download PDF

Statistics

Figures (2)

Tables (5)

Table 1. Characteristics of patients with Covid-19 based on gender. Values are expressed as percentages (numbers).

Table 2. Laboratory data of COVID-19 patients with and without oseltamivir medication regimen. Values are expressed as median rank (mean rank).

Table 3. Determining effect of oseltamivir and other factors on the treatment of COVID-19 patients using univariate logistic regression.

Table 4. Determining effect of different factors on the treatment of COVID-19 patients using multivariate logistic regression.

Table 5. Comparison of hospitalization time in the COVID-19 patients with and without oseltamivir medication regimen using logrank test.

Show moreShow less

Abstract

Introduction

Coronavirus disease 2019 (COVID-19) is the most critical issue in nowadays medicine. We aimed to evaluate the use and therapeutic outcomes of oseltamivir, an antiviral drug for patients with COVID-19.

Materials and method

In an observational study conducted at Imam Khomeini Hospital in Amol, Iran, data for 544 patients with laboratory and CT scan result confirmed COVID-19 were retrospectively collected between February 24th and April 13th 2020. To compare the characteristics of patients based on gender, the chi-square test was used. Logistic regression was used to evaluate the effect of oseltamivir on the outcome of treatment. Logrank test were used to compare the length of hospital stay in people treated with oseltamivir and drugs other than oseltamivir.

Results

Kaplan–Meier and logrank test showed no significant reduction in hospitalization time and survival rate following treatment with oseltamivir. However, a significant increase in lymphocytes count and reduction of C-reactive protein (CRP) level detected.

Conclusion

Administration of oseltamivir for patients with COVID-19 didn't show any improvement in hospitalization duration and survival rate.

Keywords:

COVID-19

Oseltamivir

Hospitalization

SARS-CoV-2

Resumen

Introducción

la enfermedad por coronavirus 2019 (COVID-19) es el tema más crítico en la medicina actual. Nuestro objetivo fue evaluar el uso y los resultados terapéuticos de oseltamivir, un medicamento antiviral para pacientes con COVID-19.

Materiales y método

en un estudio observacional realizado en el Hospital Imam Khomeini en Amol, Irán, los datos de 544 pacientes con resultados de laboratorio y tomografía computarizada confirmados de COVID-19 se recopilaron retrospectivamente entre el 24 de febrero y el 13 de abril de 2020. Para comparar las características de los pacientes en función del género se utilizó la prueba de chi-cuadrado. Se utilizó regresión logística para evaluar el efecto de oseltamivir en el resultado del tratamiento. Se utilizó la prueba de rango logarítmico para comparar la duración de la estancia hospitalaria en personas tratadas con oseltamivir y otros fármacos distintos del oseltamivir.

Resultados

Kaplan–Meier y la prueba de rango logarítmico no mostraron una reducción significativa en el tiempo de hospitalización y la tasa de supervivencia después del tratamiento con oseltamivir. Sin embargo, se detectó un aumento significativo en el recuento de linfocitos y una reducción del nivel de proteína C reactiva (PCR).

Conclusión

la administración de oseltamivir para pacientes con COVID-19 no mostró ninguna mejora en la duración de la hospitalización y la tasa de supervivencia.

Palabras clave:

COVID-19

oseltamivir

Hospitalización

SARS-CoV-2

Article

These are the options to access the full texts of the publication Vacunas (English Edition)

Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”

Subscribe to

Vacunas (English Edition)

More information

Purchase

Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now

Contact

Phone for subscriptions and reporting of errors

From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.

Calls from Spain

932 415 960

Calls from outside Spain

+34 932 415 960

E-mail

atencionalcliente@elsevier.com

Indexed in:

Follow us:

Subscribe:

Article

Subscribe to our newsletter